Javascript must be enabled to continue!
Understanding cisplatin resistance using cellular models
View through CrossRef
AbstractMany mechanisms of cisplatin resistance have been proposed from studies of cellular models of resistance including changes in cellular drug accumulation, detoxification of the drug, inhibition of apoptosis and repair of the DNA adducts. A series of resistant models were developed from CCRF‐CEM leukaemia cells with increasing doses of cisplatin from 100 ng/ml. This produced increasing resistance up to 7‐fold with a treatment dose of 1.6 μg/ml. Cisplatin resistance in these cells correlated with increases in the antioxidant glutathione, yet treatment with buthionine sulphoximine, an inhibitor of glutathione synthesis, had no effect on resistance, suggesting that the increase in glutathione was not directly involved in cisplatin resistance. Two models were developed from H69 SCLC cells, H69‐CP and H69CIS200 using 100 ng/ml or 200 ng/ml cisplatin respectively. Both cell models were 2‐4 fold resistant to cisplatin, and have decreased expression of p21 which may increase the cell's ability to progress through the cell cycle in the presence of DNA damage. Both the H69‐CP and H69CIS200 cells showed no decrease in cellular cisplatin accumulation. However, the H69‐CP cells have increased levels of cellular glutathione and are cross resistant to radiation whereas the H69CIS200 cells have neither of these changes. This suggests that increases in glutathione may contribute to cross‐resistance to other drugs and radiation, but not directly to cisplatin resistance. There are multiple resistance mechanisms induced by cisplatin treatment, even in the same cell type. How then should cisplatin‐resistant cancers be treated? Cisplatin‐resistant cell lines are often more sensitive to another chemotherapeutic drug paclitaxel (H69CIS200), or are able to be sensitized to cisplatin with paclitaxel pre‐treatment (H69‐CP). The understanding of this sensitization by paclitaxel using cell models of cisplatin resistance will lead to improvements in the clinical treatment of cisplatin resistant tumours. IUBMB Life, 59: 696‐699, 2007
Title: Understanding cisplatin resistance using cellular models
Description:
AbstractMany mechanisms of cisplatin resistance have been proposed from studies of cellular models of resistance including changes in cellular drug accumulation, detoxification of the drug, inhibition of apoptosis and repair of the DNA adducts.
A series of resistant models were developed from CCRF‐CEM leukaemia cells with increasing doses of cisplatin from 100 ng/ml.
This produced increasing resistance up to 7‐fold with a treatment dose of 1.
6 μg/ml.
Cisplatin resistance in these cells correlated with increases in the antioxidant glutathione, yet treatment with buthionine sulphoximine, an inhibitor of glutathione synthesis, had no effect on resistance, suggesting that the increase in glutathione was not directly involved in cisplatin resistance.
Two models were developed from H69 SCLC cells, H69‐CP and H69CIS200 using 100 ng/ml or 200 ng/ml cisplatin respectively.
Both cell models were 2‐4 fold resistant to cisplatin, and have decreased expression of p21 which may increase the cell's ability to progress through the cell cycle in the presence of DNA damage.
Both the H69‐CP and H69CIS200 cells showed no decrease in cellular cisplatin accumulation.
However, the H69‐CP cells have increased levels of cellular glutathione and are cross resistant to radiation whereas the H69CIS200 cells have neither of these changes.
This suggests that increases in glutathione may contribute to cross‐resistance to other drugs and radiation, but not directly to cisplatin resistance.
There are multiple resistance mechanisms induced by cisplatin treatment, even in the same cell type.
How then should cisplatin‐resistant cancers be treated? Cisplatin‐resistant cell lines are often more sensitive to another chemotherapeutic drug paclitaxel (H69CIS200), or are able to be sensitized to cisplatin with paclitaxel pre‐treatment (H69‐CP).
The understanding of this sensitization by paclitaxel using cell models of cisplatin resistance will lead to improvements in the clinical treatment of cisplatin resistant tumours.
IUBMB Life, 59: 696‐699, 2007.
Related Results
Abstract 1490: RAD51C-deficient cancer cells require DNA polymerase zeta to bypass cisplatin-induced lesion
Abstract 1490: RAD51C-deficient cancer cells require DNA polymerase zeta to bypass cisplatin-induced lesion
RAD51C is a RAD51 paralog protein that mediates RAD51 filament formation on single-stranded DNA (ssDNA) in a canonical homologous recombination (HR) pathway. This step is vital for...
Abstract 232: Cancer stem cells and cisplatin.
Abstract 232: Cancer stem cells and cisplatin.
Abstract
Introduction:
Cisplatin is an important chemotherapeutic agent, which has resulted in higher overall response rates when combined with 5-FU o...
Abstract 1598: Epigenetic priming using azacitidine improves cisplatin response in diffuse large B-cell lymphoma cell lines via endogenous retroviruses induced viral mimicry
Abstract 1598: Epigenetic priming using azacitidine improves cisplatin response in diffuse large B-cell lymphoma cell lines via endogenous retroviruses induced viral mimicry
Abstract
Background and purpose Although majority of patients with diffuse large B-cell lymphoma (DLBCL) achieve and complete remission after first-line rituximab-CH...
The effects of recombinant klotho in cisplatin‐induced ovarian failure in mice
The effects of recombinant klotho in cisplatin‐induced ovarian failure in mice
AbstractAimTo investigate whether recombinant klotho given concomitantly with cisplatin is effective in preventing cisplatin‐induced ovarian damage.MethodsThirty‐two adult female m...
Abstract 400: TIP60-mediated regulation of DNp63a is associated with cisplatin resistance
Abstract 400: TIP60-mediated regulation of DNp63a is associated with cisplatin resistance
Abstract
About 5.4 million basal and squamous cell skin cancers are diagnosed each year in the US. The chemotherapeutic drug, Cisplatin is often used to treat squamo...
Data from Disrupting Protein NEDDylation with MLN4924 Is a Novel Strategy to Target Cisplatin Resistance in Ovarian Cancer
Data from Disrupting Protein NEDDylation with MLN4924 Is a Novel Strategy to Target Cisplatin Resistance in Ovarian Cancer
<div>Abstract<p><b>Purpose:</b> Ovarian cancer has the highest mortality rate of all female reproductive malignancies. Drug resistance is a major cause of t...
Data from Disrupting Protein NEDDylation with MLN4924 Is a Novel Strategy to Target Cisplatin Resistance in Ovarian Cancer
Data from Disrupting Protein NEDDylation with MLN4924 Is a Novel Strategy to Target Cisplatin Resistance in Ovarian Cancer
<div>Abstract<p><b>Purpose:</b> Ovarian cancer has the highest mortality rate of all female reproductive malignancies. Drug resistance is a major cause of t...
CRTAC1 Enhances the Chemosensitivity of Non-Small Cell Lung Cancer to Cisplatin Via Regulating Ca
<sup>2 </sup>/NFAT/STUB1/Akt1 Axis Induced-Apoptosis
CRTAC1 Enhances the Chemosensitivity of Non-Small Cell Lung Cancer to Cisplatin Via Regulating Ca
<sup>2 </sup>/NFAT/STUB1/Akt1 Axis Induced-Apoptosis
Background: Cisplatin-based dualagent chemotherapy is the preferred first-line chemotherapy for non-small cell lung cancer (NSCLC) patients. Moreover, the sensitivity of patients t...

